Stocktoria
Vaxcyte, Inc. PCVX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-06-12
Vaxcyte, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $794.3M | $476.6M | $332.3M | $169.5M | $78.4M |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Interest expense | — | — | $0 | $2,000 | $7,000 |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Cash & equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Shareholders' equity | $2.7B | $3.3B | $1.2B | $953.6M | $284.0M |
Source: SEC EDGAR filings · CIK 0001649094 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.